Company Announcements

Further re. FundamentalVR Fund Raise

Source: RNS
RNS Number : 3953W
Tern PLC
18 August 2022
 

18 August 2022

 

Tern Plc

("Tern" or the "Company")

 

Further re. FundamentalVR Fund Raise

 

In the Company's announcement dated 11 August 2022, the Company stated that FVRVS Limited ("FundamentalVR") had closed a second tranche of its Series B fund raising round, securing an additional £5 million in new investment (the "FundamentalVR Series B second tranche") from a new institutional investor at the same valuation as the first tranche, making a total of £13.2 million raised in Series B funding at this time.

 

The Company notes that in its press release dated 11 August 2022, FundamentalVR, an independent privately held company, stated that it "has raised an additional $20 million to significantly accelerate medical skill-transfer and increase surgical proficiency through its world-leading medical simulation platform, Fundamental Surgery."

 

Tern can confirm that all the information disclosed in its announcement dated 11 August 2022 is correct and understands that the figure of $20 million referred to by FundamentalVR includes committed contingent funding yet to be received by FundamentalVR. Such funding would be at the same valuation as the FundamentalVR Series B second tranche and would not affect the book value of Tern's investment in FundamentalVR.

 

 

Enquiries

 

Tern Plc

Al Sisto (CEO)

Sarah Payne (CFO)

via IFC Advisory

 

Allenby Capital Limited

(Nominated Adviser and Broker)

David Worlidge / Alex Brearley (Corporate Finance)

Matt Butlin / Kelly Gardiner (Sales and Corporate Broking)

 

Tel: 0203 328 5656

 

IFC Advisory

(Financial PR and IR)

Tim Metcalfe

Graham Herring

Florence Chandler

 

Tel: 0203 934 6630

tern@investor-focus.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURFLFVATLIDLIF